FLEXIBLE ONCE-DAILY Dosing

XCOPRI dosing and administration options light a clear path forward for patients.

Actor portrayals.

XCOPRI dosing and administration options light a clear path forward for patients.

Split tablet icon

Convenient once-daily dosing and a half-life of 50-60 hours

Clock icon

Taken anytime, whole or crushed, with or without food

Combination pills icon

Can be taken as monotherapy or adjunctive therapy

Explore a tailored approach with once-daily XCOPRI1

Epilepsy is not a one-size-fits-all condition—treatment shouldn’t be either. Titration with XCOPRI helps you and your patients find their effective dose in a manageable way.2

XCOPRI is titrated at 2-week intervals.1

START

Begin with the initial
12.5 mg/25 mg titration pack

XCOPRI® (cenobamate tablets) CV 12.5 mg/25 mg titration pack

Weeks 1-4

CONTINUE

Titrate using the
50 mg/100 mg titration pack

XCOPRI® (cenobamate tablets) CV 50 mg/100 mg titration pack

Weeks 5-8

IF ADDITIONAL SEIZURE
REDUCTION IS NEEDED

For patients who require more than 100 mg, dosage may be increased by 50 mg/day every 2 weeks to a maximum of 400 mg/day*

Effective dosage range:
100 mg-400 mg

Lightbulb

Reaching the right dose safely may support adherence, particularly when adverse events vary across patients and drug combinations2

Liver function tests should be conducted prior to starting XCOPRI to establish baseline liver function if results are not available from the past 3 months.1

200 mg is the maximum dosage for patients with mild or moderate hepatic impairment. XCOPRI is not recommended for use in patients with severe hepatic impairment.1 See full Prescribing Information for additional dosing and administration instructions.

Zero seizure rates shown within the first titration pack1,3

FIRST 4 WEEKS RESULTSDownload additional dosing details

Flexibility to meet your patients’ unique needs1

Blister packs can simplify the titration schedule when starting XCOPRI

XCOPRI® (cenobamate tablets) CV 12.5 mg/25 mg titration pack 28-day supply

12.5 mg/25 mg (28-day supply)

XCOPRI® (cenobamate tablets) CV 50 mg/100 mg titration pack 28-day supply

50 mg/100 mg (28-day supply)

XCOPRI® (cenobamate tablets) CV 150 mg/200 mg titration pack 28-day supply

150 mg/200 mg (28-day supply)

Bottles and maintenance blister packs allow for adjustments to find the right dosage for each patient

XCOPRI® (cenobamate tablets) CV maintenance bottles

Maintenance bottles available:

• 25 mg (30-count bottle)
• 50 mg (30-count bottle)
• 100 mg (30-count bottle)
• 150 mg (30-count bottle)
• 200 mg (30-count bottle)

XCOPRI® (cenobamate tablets) CV maintenance blister packs

Maintenance blister packs available:

• 250 mg (28-day supply)
• 350 mg (28-day supply)

REQUEST SAMPLES
Michael A.L. Johnson, MD, FAAN

“A scheduled titration gives the body time to acclimate to a new therapy while allowing the clinician to monitor tolerability, potential drug-drug interactions, and early signs of efficacy.”

– Michael A.L. Johnson, MD, FAAN

Watch expert video
Graduation cap

XCOPRI & epilepsy education

See educational offerings tailored for APPs and NPs, from CME/CE-accredited courses to interactive prescriber sessions led by featured experts

Start learning today
United States

Access

XCOPRI is widely accessible with low copays. Discover support available to get started

Learn about access
  APPs=Advanced Practice Providers; CE=continuing education; CME=continuing medical education; NPs=nurse practitioners.
References: 1. XCOPRI (package insert). Paramus, NJ: SK Life Science, Inc. 2. Seiden LG, Connor GS. The importance of drug titration in the management of patients with epilepsy. Epilepsy Behav. 2022;128:108517. 3. Aboumatar S, Biton V, Wechsler R, Ferrari L, Rosenfeld WE. Post hoc analysis of a phase 3 study for treatment of uncontrolled focal seizures: adjunctive cenobamate dose and seizure reduction by baseline seizure frequency. Epilepsy Res. 2022;186:107014.
Expand

INDICATION

XCOPRI is indicated for the
treatment of partial-onset
seizures in adult patients.

Important Safety Information
and indication

CONTRAINDICATIONS
XCOPRI is contraindicated in patients with hypersensitivity to cenobamate or any of the ingredients in the product.
XCOPRI is contraindicated in patients with Familial Short QT syndrome.

Collapse IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION and INDICATION for XCOPRI® (cenobamate tablets) CV

CONTRAINDICATIONS

XCOPRI is contraindicated in patients with hypersensitivity to cenobamate or any of the ingredients in the product. 

XCOPRI is contraindicated in patients with Familial Short QT syndrome.

WARNINGS AND PRECAUTIONS

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including XCOPRI. DRESS has been reported, including one fatality, when XCOPRI is titrated rapidly (weekly or faster titration). No cases of DRESS were reported in an open-label safety study of 1339 partial-onset seizure patients when XCOPRI was initiated at 12.5 mg/day and titrated every two weeks. This finding does not establish that the risk of DRESS is prevented by a slower titration; however, XCOPRI should be initiated at 12.5 mg once daily and titrated every two weeks. DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement. Eosinophilia is often present. If such signs or symptoms are present, the patient should be evaluated immediately. XCOPRI should be discontinued immediately and not restarted if an alternative etiology for the signs or symptoms cannot be established.

QT Shortening: XCOPRI can cause shortening of the QT interval. Caution should be used when administering XCOPRI and other drugs that shorten the QT interval as there may be a synergistic effect on the QT interval that would increase the QT shortening risk.

Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including XCOPRI, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Advise patients, their caregivers, and/or families to be alert for these behavioral changes and report them immediately to a healthcare provider.

Liver Injury: Clinically significant liver injury has occurred in patients taking XCOPRI. Obtain serum transaminases (ALT and AST) and total bilirubin, if not recently available (i.e., within 3 months) before initiating XCOPRI, and during treatment if clinically indicated. Monitor patients for signs and symptoms of any hepatic injury during treatment. Discontinue XCOPRI in patients with evidence of liver injury in the absence of an alternative etiology.

Neurological Adverse Reactions: XCOPRI can cause dose-dependent increases in the neurologic adverse reactions including dizziness, diplopia, disturbance in gait and coordination, somnolence, and fatigue.

Prescribers should advise patients against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of XCOPRI is known.

Withdrawal of AEDs: As with all antiepileptic drugs, XCOPRI should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus. If withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered.

MOST COMMON ADVERSE REACTIONS

In adult adjunctive therapy placebo-controlled clinical studies, the most common adverse reactions that occurred in XCOPRI-treated patients (incidence at least 10% and greater than placebo) were somnolence, dizziness, fatigue, diplopia, headache.

DOSING CONSIDERATIONS

Dosage adjustment of XCOPRI or other concomitant medications may be necessary.

  • Consider gradually reducing phenytoin dosages by up to 50% during initial titration.
  • Consider reducing dosages of phenobarbital and clobazam as needed when used concomitantly with XCOPRI.
  • When XCOPRI and carbamazepine or lamotrigine are taken concomitantly, consider increasing dosages as needed of carbamazepine or lamotrigine.
  • Consider increasing dosages as needed of drugs which are CYP2B6 and CYP3A substrates and decreasing dosages as needed of drugs which are CYP2C19 substrates.
  • Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control.

Dosage reduction of XCOPRI may be considered in patients with mild to moderate and severe renal impairment. XCOPRI is not recommended in end-stage renal disease.

The maximum recommended daily dose is 200 mg for patients with mild or moderate hepatic impairment. XCOPRI is not recommended in patients with severe hepatic impairment.

DRUG ABUSE

XCOPRI is a Schedule V controlled substance.

INDICATION

XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.

Please see full Prescribing Information.